Literature DB >> 7518681

Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11.

L C Berger1, T S Hawley, J A Lust, S J Goldman, R G Hawley.   

Abstract

The pleiotropic cytokine interleukin (IL-6) is a major growth factor for murine plasmacytomas/hybridomas and human myeloma cells. Here we report that IL-6 stimulated different patterns of tyrosine phosphorylation of JAK-TYK kinases in IL-6-responsive murine (B9E and T10D) and human (ANBL-6 and OCI-My4) plasma cell tumor lines. Interestingly, the Stat91 transcription factor essential for interferon signaling mediated by JAK-TYK kinases was significantly tyrosine phosphorylated in response to IL-6 in ANBL-6 cells but not in the other cell lines. We further show that IL-11, a cytokine that signals via the gp130 subunit of the IL-6 receptor, induced similar profiles of JAK-TYK tyrosine phosphorylation as IL-6 in B9E and T10D cells. These results suggest that functionally redundant JAK-TYK kinase cascades triggered through gp130 are involved in the growth regulation of plasma cell neoplasms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518681     DOI: 10.1006/bbrc.1994.1970

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

Review 1.  Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Authors:  Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

2.  Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases.

Authors:  M Schaeffer; M Schneiderbauer; S Weidler; R Tavares; M Warmuth; G de Vos; M Hallek
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

3.  Negative cross-talk between interleukin-3 and interleukin-11 is mediated by suppressor of cytokine signalling-3 (SOCS-3).

Authors:  F Magrangeas; O Boisteau; S Denis; Y Jacques; S Minvielle
Journal:  Biochem J       Date:  2001-01-15       Impact factor: 3.857

Review 4.  Cytokine-like factor 1 (CLF1): life after development?

Authors:  Daniel J Kass
Journal:  Cytokine       Date:  2011-06-28       Impact factor: 3.861

5.  Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma.

Authors:  C L Campbell; Z Jiang; D M Savarese; T M Savarese
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

6.  Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.

Authors:  M Jourdan; J De Vos; N Mechti; B Klein
Journal:  Cell Death Differ       Date:  2000-12       Impact factor: 15.828

7.  Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11.

Authors:  R G Hawley; T S Hawley; A Z Fong; C Quinto; M Collins; J P Leonard; S J Goldman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

Review 8.  Tocilizumab in pediatric rheumatology: the clinical experience.

Authors:  Reut Gurion; Nora G Singer
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

9.  Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.

Authors:  Renate Burger; Steven Le Gouill; Yu-Tzu Tai; Reshma Shringarpure; Pierfrancesco Tassone; Paola Neri; Klaus Podar; Laurence Catley; Teru Hideshima; Dharminder Chauhan; Eian Caulder; Claire L Neilan; Kris Vaddi; Jun Li; Martin Gramatzki; Jordan S Fridman; Kenneth C Anderson
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

10.  INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.

Authors:  Jun Li; Margaret Favata; Jennifer A Kelley; Eian Caulder; Beth Thomas; Xiaoming Wen; Richard B Sparks; Ari Arvanitis; James D Rogers; Andrew P Combs; Kris Vaddi; Kimberly A Solomon; Peggy A Scherle; Robert Newton; Jordan S Fridman
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.